SEARCH

SEARCH BY CITATION

References

  • Ardiles A. O., Tapia-Rojas C. C., Mandal M., Alexandre F., Kirkwood A., Inestrosa N. C. and Palacios A. G. (2012) Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 109, 1383513840.
  • Arendt T. (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 118, 167179.
  • Balducci C., Mehdawy B., Mare L. et al. (2011) The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J. Alzheimers Dis. 24, 799816.
  • Benilova I., Karran E. and De Strooper B. (2012) The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349357.
  • Berg L., McKeel D. W., Jr, Miller J. P. et al. (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55, 326335.
  • Blennow K., Bogdanovic N., Alafuzoff I., Ekman R. and Davidsson P. (1996) Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J. Neural Transm. 103, 603618.
  • Bradford M. M. (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal. Biochem. 72, 248254.
  • Cheng S., Li L., He S., Liu J., Sun Y., He M., Grasing K., Premont R. T. and Suo W. Z. (2010) GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity. J. Biol. Chem. 285, 4154141548.
  • Chiodi V., Uchigashima M., Beggiato S. et al. (2012) Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 45, 983991.
  • Christensen D. Z., Kraus S. L., Flohr A., Cotel M. C., Wirths O. and Bayer T. A. (2008) Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 116, 647655.
  • Comery T. A., Martone R. L., Aschmies S. et al. (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 25, 88988902.
  • Dong H., Csernansky C. A., Martin M. V., Bertchume A., Vallera D. and Csernansky J. G. (2005) Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology 181, 145152.
  • Ferraro L., Beggiato S., Marcellino D., Frankowska M., Filip M., Agnati L. F., Antonelli T., Tomasini M. C., Tanganelli S. and Fuxe K. (2010) Nanomolar concentrations of cocaine enhance D2-like agonist-induced inhibition of the K+-evoked [3H]-dopamine efflux from rat striatal synaptosomes: a novel action of cocaine. J. Neural Transm. 117, 593597.
  • Giannakopoulos P., Herrmann F. R., Bussière T., Bouras C., Kövari E., Perl D. P., Morrison J. H., Gold G. and Hof P. R. (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 14951500.
  • Giannakopoulos P., Kövari E., Gold G., von Gunten A., Hof P. R. and Bouras C. (2009) Pathological substrates of cognitive decline in Alzheimer's disease. Front. Neurol. Neurosci. 24, 2029.
  • Hardy J. and Allsop D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383388.
  • Hardy J. A., Higgins G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184185.
  • Henley D. B., May P. C., Dean R. A. and Siemers E. R. (2009) Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin. Pharmacother. 10, 16571664.
  • Heredia L., Torrente M., Colomina M. T. and Domingo J. L. (2012) Behavioral effects of oral subacute exposure to BDE-209 in young adult mice: a preliminary study. Food Chem. Toxicol. 50, 707712.
  • Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. and Cole G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99102.
  • Imbimbo B. P., Del Giudice E., Colavito D. et al. (2007) 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822830.
  • Imbimbo B. P., Hutter-Paier B., Villetti G., Facchinetti F., Cenacchi V., Volta R., Lanzillotta A., Pizzi M. and Windisch M. (2009) CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 156, 982993.
  • Imbimbo B. P., Giardino L., Sivilia S. et al. (2010) CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 20(1), 159173.
  • Jazi R., Lalonde R., Qian S. and Strazielle C. (2009) Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice. Neurosci. Res. 63, 106114.
  • Karanth S., Liu J., Mirajkar N. and Pope C. (2006) Effects of acute chlorpyrifos exposure on in vivo acetylcholine accumulation in rat striatum. Toxicol. Appl. Pharmacol. 216, 150156.
  • Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H. and Younkin S. G. (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372381.
  • Klingner M., Apelt J., Kumar A., Sorger D., Sabri O., Steinbach J., Scheunemann M. and Schliebs R. (2003) Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology. Int. J. Dev. Neurosci. 21, 357369.
  • Knobloch M., Konietzko U., Krebs D. C. and Nitsch R. M. (2007) Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice. Neurobiol. Aging 28, 12971306.
  • Lue L. F., Kuo Y. M., Roher A. E., Brachova L., Shen Y., Sue L., Beach T., Kurth J. H., Rydel R. E. and Rogers J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853862.
  • Mangialasche F., Solomon A., Winblad B., Mecocci P. and Kivipelto M. (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702716.
  • McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. and Masters C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860866.
  • Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K. and Matsuoka N. (2012) Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32, 20372050.
  • Moreno E., Vaz S. H., Cai N. S. et al. (2011) Dopamine-galanin receptor heteromers modulate cholinergic neurotransmission in the rat ventral hippocampus. J. Neurosci. 31, 74127423.
  • Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T. and Nabeshima T. (2007) Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J. 21, 21352148.
  • Penzes P. and Vanleeuwen J. E. (2011) Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease. Brain Res. Rev. 67, 184192.
  • Peretto I., Radaelli S., Parini C. et al. (2005) Synthesis and biological activity of flubiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J. Med. Chem. 48, 57055720.
  • Puoliväli J., Wang J., Heikkinen T., Heikkilä M., Tapiola T., van Groen T. and Tanila H. (2002) Hippocampal Aβ 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol. Dis. 9, 339347.
  • Raiteri L., Luccini E., Romei C., Salvadori S. and Calò G. (2009) Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br. J. Pharmacol. 157, 474481.
  • Schliebs R. and Arendt T. (2011) The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 221, 555563.
  • Scholtzova H., Wadghiri Y. Z., Douadi M., Sigurdsson E. M., Li Y. S., Quartermain D., Banerjee P. and Wisniewski T. (2008) Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J. Neurosci. Res. 86, 27842791.
  • Schor N. F. (2011) What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann. Neurol. 69, 237239.
  • Selkoe D. J. (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106113.
  • Shankar G. M., Li S., Mehta T. H. et al. (2008) Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837842.
  • Watanabe T., Yamagata N., Takasaki K., Sano K., Hayakawa K., Katsurabayashi S., Egashira N., Mishima K., Iwasaki K. and Fujiwara M. (2009) Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. 1249, 222228.
  • Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., Carlson G. A., Younkin S. G. and Ashe K. H. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 18581867.
  • Wolfe M. S. (2012) γ-Secretase inhibitors and modulators for Alzheimer's disease. J. Neurochem. 120(Suppl 1), 8998.
  • Zhang W., Bai M., Xi Y., Hao J., Liu L., Mao N., Su C., Miao J. and Li Z. (2012) Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction. Free Radic. Biol. Med. 52, 14431452.